论文部分内容阅读
胃肠道间质瘤(GIST)是胃肠道最常见的间叶来源肿瘤。外科切除是最佳的治疗手段,伊马替尼是目前最有效的治疗药物。由于耐药的存在,部分患者预后不佳。机体的免疫状态与肿瘤进展密切相关,且肿瘤的免疫治疗具有良好的前景,大量研究探索了GIST与免疫的关系并尝试进行GIST的免疫治疗。GIST肿瘤组织内存在大量浸润的巨噬细胞、淋巴细胞、树突状细胞(DC)、自然杀伤(NK)细胞等免疫细胞,且这些细胞的亚型、数量和表型与肿瘤的临床病理特征及预后密切相关。在药物治疗过程中,免疫细胞及相关细胞因子也发挥了重要作用。GIST的免疫治疗也取得了较好的疗效,尤其是基于免疫检查点的治疗具有良好的前景。
Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor of the gastrointestinal tract. Surgical resection is the best treatment and imatinib is the most effective treatment currently available. Due to the existence of drug resistance, some patients have poor prognosis. The immune status of the body is closely related to the progress of the tumor, and the immunotherapy of the tumor has a good prospect. A large number of studies have explored the relationship between the immune of GIST and the immunization of GIST. A large number of immune cells such as macrophages, lymphocytes, dendritic cells (DCs) and natural killer (NK) cells exist in GIST tumor tissues. The subtype, number and phenotype of these cells are associated with the clinicopathological features of the tumor And the prognosis is closely related. In the process of drug treatment, immune cells and related cytokines also play an important role. GIST immunotherapy has also achieved good results, especially based on immune checkpoint treatment has good prospects.